Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug–food interaction prediction tool

Food Science and Nutrition

Volumn 2, Issue 5, 2014, Pages 500-520

  Koe, Xue Fen ^a   Tengku Muhammad, Tengku Sifzizul ^b   Chong, Alexander Shu Chien ^a,c   Wahab, Habibah Abdul ^a,d   Tan, Mei Lan ^a,e  

^a Kemeneterian Sains Teknologi dan Inovasi   (Malaysia)

^b UNIVERSITI MALAYSIA TERENGGANU   (Malaysia)

^c SCHOOL OF PHYSICS   (Malaysia)

^d SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^e ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

Author keywords

CYP1A2; CYP2D6; CYP3A4; drug food interactions; multiplex RT qPCR

Indexed keywords

EID: 84983182618     PISSN: None     EISSN: 20487177     Source Type: Journal    
DOI: 10.1002/fsn3.122     Document Type: Article

References (55)

1. Aluru, N., and M. M. Vijayan. 2006. Resveratrol affects CYP1A expression in rainbow trout hepatocytes. Aquat. Toxicol. 77:291–297.
2. Boullata, J. I. 2013. Drug and nutrition interactions: not just food for thought. J. Clin. Pharm. Ther. 38:269–271.
3. Boullata, J. I., and L. M. Hudson. 2012. Drug–nutrient interactions: a broad view with implications for practice. J. Acad. Nutr. Diet. 112:506–517.
4. Bowen, W. P., J. E. Carey, A. Miah, H. F. McMurray, P. W. Munday, R. S. James, et al. 2000. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 28:781–788.
5. Bramer, S. L., and A. Suri. 1999. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. Clin. Pharmacokinet. 37(Suppl. 2):41–51.
6. Chow, H. H., L. L. Garland, C. H. Hsu, D. R. Vining, W. M. Chew, J. A. Miller, et al. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila) 3:1168–1175.
7. Diaconu, C. H., M. Cuciureanu, L. Vlase, and R. Cuciureanu. 2011. Food–drug interactions: grapefruit juice. Rev. Med. Chir. Soc. Med. Nat. Iasi 115:245–250.
8. Diaz, D., I. Fabre, M. Daujat, B. Saint Aubert, P. Bories, H. Michel, et al. 1990. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99:737–747.
9. Dolton, M. J., B. D. Roufogalis, and A. J. McLachlan. 2012. Fruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptides. Clin. Pharmacol. Ther. 92:622–630.
10. Duret, C., M. Daujat-Chavanieu, J. M. Pascussi, L. Pichard-Garcia, P. Balaguer, J. M. Fabre, et al. 2006. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol. Pharmacol. 70:329–339.
11. Ekroos, M., and T. Sjogren. 2006. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA 103:13682–13687.
12. Fahmi, O. A., M. Kish, S. Boldt, and R. S. Obach. 2010. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab. Dispos. 38:1605–1611.
13. FDA. 2006. Guidance for Industry: Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations - Draft Guidelines. Food and Drug Administration, Silver Spring, MD.
14. FDA. 2012. Guidance for Industry: Drug Interaction Studies —Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations - Draft Guidelines. Food and Drug Administration, Silver Spring, MD.
15. Graber-Maier, A., K. B. Buter, J. Aeschlimann, C. Bittel, M. Kreuter, J. Drewe, et al. 2010. Effects of Curcuma extracts and curcuminoids on expression of P-glycoprotein and cytochrome P450 3A4 in the intestinal cell culture model LS180. Planta Med. 76:1866–1870.
16. Gurley, B. J., A. Swain, M. A. Hubbard, D. K. Williams, G. Barone, F. Hartsfield, et al. 2008. Clinical assessment of CYP2D6-mediated herb–drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol. Nutr. Food Res. 52:755–763.
17. Hellum, B. H., Z. Hu, and O. G. Nilsen. 2006. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin. Pharmacol. Toxicol. 100:8.
18. Huang, H., H. Wang, M. Sinz, M. Zoeckler, J. Staudinger, M. R. Redinbo, et al. 2007. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268.
19. Hukkanen, J. 2012. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev. Clin. Pharmacol. 5:569–585.
20. Ideker, T., V. Thorsson, J. A. Ranish, R. Christmas, J. Buhler, J. K. Eng, et al. 2001. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292:929–934.
21. Jauregui-Garrido, B., and I. Jauregui-Lobera. 2012. Interactions between antiarrhythmic drugs and food. Nutr. Hosp. 27:1399–1407.
22. Kelly, J. H., and N. L. Sussman. 2000. A fluorescent cell-based assay for cytochrome P-450 isozyme 1A2 induction and inhibition. J. Biomol. Screen. 5:249–254.
23. Komoroski, B. J., S. Zhang, H. Cai, J. M. Hutzler, R. Frye, T. S. Tracy, et al. 2004. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos. 32:512–518.
24. Lin, J. H. 2006. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm. Res. 23:1089–1116.
25. Lin, H. L., C. Kenaan, and P. F. Hollenberg. 2012. Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab. Dispos. 40:998–1006.
26. Lown, K. S., D. G. Bailey, R. J. Fontana, S. K. Janardan, C. H. Adair, L. A. Fortlage, et al. 1997. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Investig. 99:2545–2553.
27. Lynch, T., and A. Price. 2007. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76:391–396.
28. Madan, A., R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, et al. 2003. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 31:421–431.
29. Maier, T., M. Guell, and L. Serrano. 2009. Correlation of mRNA and protein in complex iological samples. FEBS Lett. 583:3966–3973.
30. Nelson, D. R., L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, et al. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42.
31. Ogu, C. C., and J. L. Maxa. 2000. Drug interactions due to cytochrome P450. Proc. (Bayl. Univ. Med. Cent.) 13:421–423.
32. Pekthong, D., H. Martin, C. Abadie, A. Bonet, B. Heyd, G. Mantion, et al. 2008. Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide. J. Ethnopharmacol. 115:432–440.
33. Pekthong, D., N. Blanchard, C. Abadie, A. Bonet, B. Heyd, G. Mantion, et al. 2009. Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures. Chem. Biol. Interact. 179:247–255.
34. Pelkonen, O., M. Turpeinen, J. Hakkola, P. Honkakoski, J. Hukkanen, and H. Raunio. 2008. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 82:667–715.
35. Pirmohamed, M. 2013. Drug-grapefruit juice interactions. BMJ 346:f1.
36. Regev-Shoshani, G., O. Shoseyov, and Z. Kerem. 2004. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem. Biophys. Res. Commun. 323:668–673.
37. Roby, C. A., G. D. Anderson, E. Kantor, D. A. Dryer, and A. H. Burstein. 2000. St. John's wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther. 67:451–457.
38. Rodeiro, I., M. T. Donato, A. Lahoz, G. Garrido, R. Delgado, and M. J. Gomez-Lechon. 2008. Interactions of polyphenols with the P450 system: possible implications on human therapeutics. Mini. Rev. Med. Chem. 8:97–106.
39. Ruhl, R., R. Sczech, N. Landes, P. Pfluger, D. Kluth, and F. J. Schweigert. 2004. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur. J. Nutr. 43:336–343.
40. Sesardic, D., A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. de la Torre, et al. 1990. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29:651–663.
41. Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414–423.
42. Shin, J. G., N. Soukhova, and D. A. Flockhart. 1999. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab. Dispos. 27:1078–1084.
43. Shirasaka, Y., J. E. Sager, J. D. Lutz, C. Davis, and N. Isoherranen. 2013. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug–drug interactions. Drug Metab. Dispos. 41:1414–1424.
44. Sunaga, K., K. Ohkawa, K. Nakamura, A. Ohkubo, S. Harada, and T. Tsuda. 2012. Mechanism-based inhibition of recombinant human cytochrome P450 3A4 by tomato juice extract. Biol. Pharm. Bull. 35:329–334.
45. Tian, Q., S. B. Stepaniants, M. Mao, L. Weng, M. C. Feetham, M. J. Doyle, et al. 2004. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteomics 3:960–969.
46. Venkatakrishnan, K., L. L. Von Moltke, and D. J. Greenblatt. 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 41:1149–1179.
47. Volak, L. P., M. J. Hanley, G. Masse, S. Hazarika, J. S. Harmatz, V. Badmaev, et al. 2013. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol. 75:450–462.
48. Walsky, R. L., and S. E. Boldt. 2008. In vitro cytochrome P450 inhibition and induction. Curr. Drug Metab. 9:928–939.
49. Wen, Y. H., J. Sahi, E. Urda, S. Kulkarni, K. Rose, X. Zheng, et al. 2002. Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. Drug Metab. Dispos. 30:977–984.
50. Westerink, W. M., and W. G. Schoonen. 2007. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21:1581–1591.
51. Wrighton, S. A., E. G. Schuetz, K. E. Thummel, D. D. Shen, K. R. Korzekwa, and P. B. Watkins. 2000. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32:339–361.
52. Yan, Z., and G. W. Caldwell. 2001. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 1:403–425.
53. Zanger, U., S. Raimundo, and M. Eichelbaum. 2004. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369:23–37.
54. Zhou, S. F., Z. W. Zhou, C. G. Li, X. Chen, X. Yu, C. C. Xue, et al. 2007. Identification of drugs that interact with herbs in drug development. Drug Discov. Today 12:664–673.
55. Zlokarnik, G., P. D. Grootenhuis, and J. B. Watson. 2005. High throughput P450 inhibition screens in early drug discovery. Drug Discov. Today 10:1443–1450.